Burzynski Research (BZYR) 0.2400 $BZYR
Burzynski Research Institute, Inc. Announces Presentations at the 16th International Symposium on Pediatric Neuro-Oncology
PR Newswire - Fri Jun 27, 12:08PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014. Abstracts and presentations are now available to the public in an online supplement in the journal, Neuro-Oncology (Neuro Oncol 2014 June; 16(Suppl 1): i1-i157). The abstract numbers are CT-004, HG-017, and MB-039. The journal's TOC web address is http://neuro-oncology.oxfordjournals.org/cont...uppl_1.toc.
Burzynski Research Institute, Inc. Announces Lifting of the FDA Partial Clinical Hold - Phase 3 Clinical Study Agreed Upon
PR Newswire - Mon Jun 23, 3:07PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted. The FDA has determined that under its IND the Company may initiate its planned Phase 3 study in newly diagnosed diffuse, intrinsic, brainstem glioma. The Company is continuing discussions with the Agency in an effort to finalize additional details of the phase 3 study protocol for the potential clinical trial.
Global Ependymoma Clinical Trials Review Report - H2 2013 Edition
M2 - Mon Jan 13, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rrpdm/ependymoma_global) has announced the addition of the "Ependymoma Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Ependymoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ependymoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Ependymoma Therapeutics Clinical Trials - Advantagene, Inc. - Astellas US Holding, Inc. - Burzynski Research Institute, Inc. - DNAtrix, Inc. - Direct Therapeutics, Inc. - Eli Lilly and Company Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - St. Jude Children's Research Hospital, Inc. - Children's Oncology Group - The University of Texas M. D. Anderson Cancer Center - City of Hope National Medical Center - Children's Cancer and Leukaemia Group - Massachusetts General Hospital - Northwestern University - Cancer Research UK - Memorial Sloan Kettering Cancer Center For more information visit http://www.researchandmarkets.com/research/9r...oma_global
Astrocytoma Global Clinical Trials Review, H2, 2012
M2 - Fri Jan 18, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnsfxh/astrocytoma) has announced the addition of GlobalData's new report "Astrocytoma Global Clinical Trials Review, H2, 2012" to their offering. Astrocytoma Global Clinical Trials Review, H2, 2012" provides data on the Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Astrocytoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in
Burzynski Research Institute, Inc. Announces Presentations at the 16th International Symposium on Pediatric Neuro-Oncology
PR Newswire - Fri Jun 27, 12:08PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that it will present data on two of the Company's clinical-stage product candidates, Antineoplaston A10 injections (Atengenal®) and Antineoplaston AS2-1 injections (Astugenal®), at the 16th International Symposium on Pediatric Neuro-Oncology held in Singapore from June 28, 2014 to July 2, 2014. Abstracts and presentations are now available to the public in an online supplement in the journal, Neuro-Oncology (Neuro Oncol 2014 June; 16(Suppl 1): i1-i157). The abstract numbers are CT-004, HG-017, and MB-039. The journal's TOC web address is http://neuro-oncology.oxfordjournals.org/cont...uppl_1.toc.
Burzynski Research Institute, Inc. Announces Lifting of the FDA Partial Clinical Hold - Phase 3 Clinical Study Agreed Upon
PR Newswire - Mon Jun 23, 3:07PM CDT
The Burzynski Research Institute, Inc. (BRI) announced today that U.S. Food and Drug Administration (FDA) has notified the company that its partial clinical hold on its IND for Antineoplastons A10/AS2-1 Injections has been lifted. The FDA has determined that under its IND the Company may initiate its planned Phase 3 study in newly diagnosed diffuse, intrinsic, brainstem glioma. The Company is continuing discussions with the Agency in an effort to finalize additional details of the phase 3 study protocol for the potential clinical trial.
Global Ependymoma Clinical Trials Review Report - H2 2013 Edition
M2 - Mon Jan 13, 10:22AM CST
Research and Markets (http://www.researchandmarkets.com/research/9rrpdm/ependymoma_global) has announced the addition of the "Ependymoma Global Clinical Trials Review, H2, 2013" report to their offering. This report provides elemental information and data relating to the clinical trials on Ependymoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Ependymoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Ependymoma Therapeutics Clinical Trials - Advantagene, Inc. - Astellas US Holding, Inc. - Burzynski Research Institute, Inc. - DNAtrix, Inc. - Direct Therapeutics, Inc. - Eli Lilly and Company Clinical Trial Overview of Top Institutes / Government - National Cancer Institute - St. Jude Children's Research Hospital, Inc. - Children's Oncology Group - The University of Texas M. D. Anderson Cancer Center - City of Hope National Medical Center - Children's Cancer and Leukaemia Group - Massachusetts General Hospital - Northwestern University - Cancer Research UK - Memorial Sloan Kettering Cancer Center For more information visit http://www.researchandmarkets.com/research/9r...oma_global
Astrocytoma Global Clinical Trials Review, H2, 2012
M2 - Fri Jan 18, 3:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/nnsfxh/astrocytoma) has announced the addition of GlobalData's new report "Astrocytoma Global Clinical Trials Review, H2, 2012" to their offering. Astrocytoma Global Clinical Trials Review, H2, 2012" provides data on the Astrocytoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Astrocytoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Astrocytoma. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in
